Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies

JAMA

Volumn 296, Issue 16, 2006, Pages 2005-2011

  Patel, Priti R ^a,c   Larson, A Kirsten ^c   Castel, Amanda D ^a,c   Ganova Raeva, Lilia M ^b   Myers, Robert A ^c   Roup, Brenda J ^c   Farrell, Katherine P ^d   Edwards, Leslie ^c   Nainan, Omana ^b   Krick, John P ^c   Blythe, David ^c   Fiore, Anthony E ^b   Roche, Jeffrey C ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d Anne Arundel County Department of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG CONTAMINATION; FEMALE; HEART MUSCLE PERFUSION; HEPATITIS C; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; VIRUS TRANSMISSION;

EID: 33750347505     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.16.2005     Document Type: Article

References (41)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
2. Centers for Disease Control and Prevention. Transmission of hepatitis B and C viruses in outpatient settings - New York, Oklahoma, and Nebraska, 2000-2002. MMWR Morb Mortal Wkly Rep. 2003;52:901-906.
3. Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings. Clin Infect Dis. 2004;38:1592-1598.
4. Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005;142:898-902.
5. Comstock RD, Mallonee S, Fox JL, et al. A large nosocomial outbreak of hepatitis C and hepatitis B among patients receiving pain remediation treatments. Infect Control Hosp Epidemiol. 2004;25:576-583.
6. Krause G, Trepka MJ, Whisenhunt RS, et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol. 2003;24:122-127.
7. Lagging LM, Aneman C, Nenonen N, et al. Nosocomial transmission of HCV in a cardiology ward during the window period of infection: an epidemiological and molecular investigation. Scand J Infect Dis. 2002;34:580-582.
8. Massari M, Petrosillo N, Ippolito G, et al. Transmission of hepatitis C virus in a gynecological surgery setting. J Clin Microbiol. 2001;39:2860-2863.
9. Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Etoh Y, Hayashi J. Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol. 2004;25:584-590.
10. Forns X, Martinez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology. 2005;41:115-122.
11. Silini E, Locasciulli A, Santoleri L, et al. Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome. Haematologica. 2002;87:1200-1208.
12. Janowski MC, Gunn RA, Chai F, et al. Transmission of hepatitis C virus at a pain remediation clinic-San Diego, California in 2003. Presented at: Infectious Diseases Society of America 43rd Annual Meeting; October 6-9, 2005; San Francisco, Calif.
13. Medical Information Division IMV. 2005 Nuclear Medicine Market Summary Report. http://www.imvlimited.com/mid/nucmed_census.html#. Accessed September 17, 2006.
14. Callahan RJ. The role of commercial nuclear pharmacy in the future practice of nuclear medicine. Semin Nucl Med. 1996;2:85-90.
15. Cody SH, Nainan OV, Garfein RS, et al. Hepatitis Cvirus transmission from an anesthesiologist to a patient. Arch Intern Med. 2002;162:345-350.
16. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
17. Felsenstein J. PHYLIP (Phylogeny Inference Package), Version 3.5. Seattle: Department of Genetics, University of Washington; 1993.
18. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution Int J Org Evolution. 1985;39:783-791.
19. Krawczynski K, Alter MJ, Robertson BH, Lu L, Spelbring JE, McCaustland KA. Environmental stability of hepatitis C virus (HCV): viability of dried/stored HCV in chimpanzee infectivity studies. In: Program and Abstracts of the 54th Annual Meeting of the American Society for the Study of Liver Disease. Philadelphia, Pa: WB Saunders; 2003.
20. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 2001;50(RR-11):1-42.
21. Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med. 1997;336:919-922.
22. Ciesielski CA, Metler RP. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med. 1997;102(suppl 5B):115-116.
23. Purdue University Division of Nuclear Pharmacy. List of nuclear pharmacies in the United States. http://nuclear.pharmacy.purdue.edu/nukeinus/ regionlist.php?region=24). Accessed May 16, 2005.
24. Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis. 2006;43:831-837.
25. Held MR, Begier EM, Beardsley DS, et al. Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics. 2006;118:e212-e215.
26. Perz JF, Craig AS, Stratton CW, Bodner SJ, Phillips WE, Schaffner W. Pseudomonas putida septicemia in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. J Clin Microbiol. 2005;43:5316-5318.
27. Centers for Disease Control and Prevention. Pseudomonas bloodstream infections associated with a heparin/saline flush - Missouri, New York, Texas, and Michigan, 2004-2005.MMWR Morb Mortal Wkly Rep. 2005;54:269-272.
28. Sunenshine RH, Tan ET, Kazakova S, et al. Multistate outbreak of Serratia marcescens bloodstream infections associated with contaminated intravenous magnesium sulfate. Presented at: Infectious Diseases Society of America 43rd Annual Meeting; October 6-9, 2005; San Francisco, Calif.
29. Centers for Disease Control and Prevention. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy - United States, July-November 2002. MMWR Morb Mortal Wkly Rep. 2002;51:1109-1112.
30. Pegues DA. Improving and enforcing compounding pharmacy practices to protect patients. Clin Infect Dis. 2006;43:838.
31. Trissel LA. Compounding our problems - again. Am J Health Syst Pharm. 2003;60:432.
32. Young D. Senate mulls oversight of pharmacy compounding. Am J Health Syst Pharm. 2003;60:2402-2406.
33. Sabra K. Standards for pharmacy compounding. Am J Health Syst Pharm. 2003;60:1593.
34. Newton DW. Compounding paradox: taught less and practiced more. Am J Pharm Educ. 2003;67:12-14.
35. Kastango ES. The cost of quality in pharmacy. Int J Pharm Compound. 2002;6:404-407.
36. Young D. Outsourced compounding can be problematic: community pharmacies linked to contaminated injectables. Am J Health Syst Pharm. 2002;59:2261-2264.
37. Morris AM, Schneider PJ, Pedersen CA, Mirtallo JM. National survey of quality assurance activities for pharmacy-compounded sterile preparations. Am J Health Syst Pharm. 2003;60:2567-2576.
38. US Pharmacopeia Inc. Pharmaceutical Compounding - Sterile Preparations. Rockville, Md: US Pharmacopeial Convention; 2004:2461-2477.
39. Kastango ES, Bradshaw BD. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm. 2004;61:1928-1938.
40. Nuclear Pharmacy Compounding Practice Committee; Section on Nuclear Pharmacy Practice, American Pharmaceutical Association. Nuclear pharmacy compounding guidelines. http://www.aphanet.org/AM/Template.cfm?Section= Search§ion=APPM&template=/CM/ContentDisplay.cfm&ContentFileID= 217. Accessed September 11, 2006.
41. National Association of Boards of Pharmacy. Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy. http://www.nabp.net/ftpfiles/NABP01/ModelActFINAL.doc. Accessed September 11, 2006.